公开(公告)号：US20230151007A1

公开(公告)日：2023-05-18

申请号：US17983097

申请日：2022-11-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Upender Velaparthi ,  Richard E. Olson ,  Chetan Padmakar Darne ,  Bireshwar Dasgupta ,  Jayakumar Sankara Warrier ,  Hasibur Rahaman ,  Prasada Rao Jalagam ,  Saumya Roy ,  Denise Christine Grunenfelder

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Disclosed are compounds of Formula (I):





or a salt thereof, wherein: R1, R2, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKξ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

公开(公告)号：US20220324859A1

公开(公告)日：2022-10-13

申请号：US17164009

申请日：2021-02-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Upender Velaparthi ,  Louis S. Chupak ,  Chetan Padmakar Darne ,  Min Ding ,  Robert G. Gentles ,  Yazhong Huang ,  Manjunatha Narayana Rao Kamble ,  Scott W. Martin ,  Raju Mannoori ,  Ivar M. McDonald ,  Richard E. Olson ,  Hasibur Rahaman ,  Prasada Rao Jalagam ,  Saumya Roy ,  Gopikishan Tonukunuru ,  Sivasudar Velaiah ,  Jayakumar Sankara Warrier ,  Xiaofan Zheng ,  John S. Tokarski ,  Bireshwar Dasgupta ,  Kotha Rathnakar Reddy ,  Thiruvenkadam Raja

IPC: C07D471/04

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

公开(公告)号：US10959986B2

公开(公告)日：2021-03-30

申请号：US16555634

申请日：2019-08-29

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron Balog ,  Steven P. Seitz ,  Susheel Jethanand Nara ,  Saumya Roy ,  Srinivasan Thangathirupathy ,  Soodamani Thangavel ,  Ramesh Kumar Sistla

IPC: A61K31/415 ,  A61K31/5377 ,  C07D231/12 ,  C07D401/12 ,  C07D403/12 ,  C07D261/08 ,  C07D277/22 ,  C07D285/08 ,  C07D211/60 ,  C07D317/50 ,  C07D307/36 ,  C07D333/54 ,  C07D231/56 ,  C07D221/22 ,  C07D471/04 ,  C07D487/04 ,  A61K31/17 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/42 ,  A61K31/426 ,  A61K31/433 ,  A61K31/357 ,  A61K31/341 ,  A61K31/381 ,  C07C275/42

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.

公开(公告)号：US20210061802A1

公开(公告)日：2021-03-04

申请号：US17004058

申请日：2020-08-27

Applicant: Bristol-Myers Squibb Company

Inventor： Upender Velaparthi ,  Richard E. Olson ,  Chetan Padmakar Darne ,  Bireshwar Dasgupta ,  Jayakumar Sankara Warrier ,  Hasibur Rahaman ,  Prasada Rao Jalagam ,  Saumya Roy ,  Denise Christine Grunenfelder

IPC: C07D471/04

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

公开(公告)号：US20200069695A1

公开(公告)日：2020-03-05

申请号：US16555431

申请日：2019-08-29

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron Balog ,  Steven P. Seitz ,  Susheel Jethanand Nara ,  Saumya Roy ,  Srinivasan Thangathirupathy ,  Soodamani Thangavel ,  Srinivas Cheruku

IPC: A61K31/5377 ,  C07C275/42 ,  A61K31/17 ,  C07D277/64 ,  A61K31/428 ,  C07C211/54 ,  A61K31/136 ,  C07D239/47 ,  A61K31/505 ,  A61K31/275 ,  C07D241/18 ,  A61K31/4965 ,  C07D239/42 ,  A61K31/5375 ,  C07D295/03 ,  C07D413/12

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.